D
DaVita Inc.
DVA · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
A Toll Booth Business Where the Road May Be Rerouting
Most investors anchoring on the cheap multiple and durable cash flows are treating this as a stable compounder — the harder question is whether DaVita is a mature harvest asset whose patient funnel is quietly narrowing in real time, with a balance sheet too leveraged to handle a demand curve that bends the wrong way.
Flowly Score
Apr 16 Close
+238%$148.13
Fair Value
$500.00
51
Averageat $148.13
Business Strength6/10
The captive patient model and duopoly structure create a genuine moat, but pricing power belongs to CMS, not DaVita — this is a regulated utility dressed as a healthcare business, with governance baggage that demands a permanent discount.
Financial Resilience5/10
Cash generation quality is genuinely excellent — profits are real and consistent — but the balance sheet tells a different story: leverage has ballooned sharply, the Altman Z sits in distress territory, and there is almost no equity cushion if reimbursement rates move against them.
Growth & Trajectory4/10
Volume is expected to be flat in 2026 with a path to only 2% growth over three years, and EPS expansion is almost entirely a buyback story rather than underlying business growth — the IKC profitability milestone is genuinely encouraging but too small to move the needle yet.
Valuation8/10at $152.56
At a low-teens multiple with a double-digit free cash flow yield, the market is pricing this as if the bad outcome is already happening — even applying a substantial haircut for leverage risk and GLP-1 uncertainty, the current price embeds a pessimism that the trailing numbers do not support.
Risk3/10
Three serious risks are stacked simultaneously: Medicare reimbursement is the entire economic engine with no escape valve, GLP-1 drugs are a slow-motion demand destruction story that won't show up for years, and the balance sheet carries enough leverage that a rate cut or volume shock has genuine solvency implications rather than just earnings pressure.
The investment case rests on a genuine tension: this is an operationally solid, cash-generative business trading at a multiple that implies the market has already written off the growth story. For a business with deeply captive patients, a duopoly structure, and a management team that returns cash with discipline, that multiple looks like an opportunity — particularly when the free cash flow yield is this high and the buyback engine is compounding per-share value even when total company earnings are flat. The IKC pivot reaching profitability ahead of schedule hints at a business that can expand its clinical footprint rather than simply maintain it. But the trajectory question is where second-level thinking is essential. DaVita's core volume growth has been demographically reliable for decades — a self-refilling annuity built on the twin epidemics of diabetes and hypertension. GLP-1 drugs attack exactly those root causes, and their effectiveness at slowing kidney disease progression is not speculative anymore. The impact won't show in the next two years, but terminal value assumptions built on steady patient census growth deserve a serious haircut. Management is threading this needle by targeting clinical improvements to retain existing patients better — reducing mortality and missed treatments — as a partial offset, but that is retention management, not demand creation. The single biggest risk is the combination of high leverage meeting a CMS rate revision. DaVita has essentially no pricing power and a balance sheet with almost no equity cushion — it is running on the operational cash engine with very little shock absorption. A meaningful adverse change to Medicare bundled payment rates would compress margins in a business that cannot respond by raising prices, against a debt load that cannot simply be absorbed. That is not a tail scenario; CMS has repriced dialysis before, and a federal budget under sustained pressure has every incentive to target a service that costs dramatically more per patient in the US than anywhere else on earth.